DGRW vs IBB
WisdomTree US Quality Dividend Growth Fund vs iShares Biotechnology ETF
- • DGRW has the lower expense ratio at 0.28% vs 0.44% for IBB.
- • DGRW pays a higher dividend yield (1.24%).
Side-by-side metrics
| Metric | DGRW | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.28% | 0.44% |
Dividend yield Trailing 12-month yield. | 1.24% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $16.93B | $11.50B |
YTD return | 11.01% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.78 | 0.60 |
P/E ratio | 24.10 | 25.48 |
Last price | $98.82 | $217.75 |
Inception | — | — |
Issuer | WisdomTree | iShares |
DGRW top holdings
| NVDA | NVIDIA Corp | 7.89% |
| MSFT | Microsoft Corp | 7.81% |
| AAPL | Apple Inc | 4.47% |
| KO | Coca-Cola Co | 3.24% |
| META | Meta Platforms Inc Class A | 3.15% |
| UNH | UnitedHealth Group Inc | 2.78% |
| HD | The Home Depot Inc | 2.54% |
| JNJ | Johnson & Johnson | 2.45% |
| ABBV | AbbVie Inc | 2.36% |
| XOM | ExxonMobil Holdings Corp | 2.12% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About DGRW
DGRW (WisdomTree US Quality Dividend Growth Fund) is Dividend-paying US large caps with quality and growth screens. Managed by WisdomTree, the fund carries $16.9B in assets under management, an expense ratio of 0.28%, a dividend yield of 1.24%. Its largest holding is NVIDIA Corp (NVDA), which represents 7.9% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 7.3%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.